The association of the neutrophil lymphocyte ratio with the presence of minimal residual disease and outcome in patients with stage ii colon cancer treated with surgery alone

Simple item page
dc.contributor.authorMurray, Nigel P
dc.contributor.authorVillalon, Ricardo
dc.contributor.authorOrrego, Shenda
dc.contributor.authorGuzman, Eghon
dc.date.accessioned2021-12-17T12:14:44Z
dc.date.available2021-12-17T12:14:44Z
dc.date.issued2021-04
dc.description.abstractAbstract Aim: Despite curative surgery, 25% of patients with Stage II colorectal cancer will relapse due to minimal residual disease (MRD). Markers of immune function, such as the neutrophil to lymphocyte ratio (NLR), may be associated with MRD defined by bone marrow micro-metastasis (mM) and circulating tumour cells (CTCs). Method: A prospective cohort study of consecutive patients with Stage II colon cancer patients attended at a single centre between 2007 and 2014. Blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anticarcinoembryonic antigen 1 month after surgery. The NLR and absolute neutrophil and lymphocyte counts were determined immediately pre-surgery and 1 month post-surgery. These were compared with the sub-types of MRD: group I MRD(−); group II mM positive and group III CTC positive. Cut-off values of the NLR of >3.0 and >5.0 were used. Follow-up was for up to 5 years or relapse and disease-free survival (DFS) was calculated using Kaplan–Meier analysis. Results: In all, 181 patients (99 women) participated. Mean age was 68 years. Median follow-up was 4.04 years: I, N = 105; II, N = 36; III, N = 40. The NLR significantly decreased post-surgery only in group I patients. The frequency of NLR >3.0 and >5.0 was significantly higher in group III; between groups I and II there was no significant difference. 5-year DFS was 98% in group I, 68% in group II and 7% in group III. Conclusions: Patients with a significantly higher immune dysfunction had a shorter time to disease progression, a worse DFS and the presence of CTCs.es
dc.description.sponsorshipFunded by the Western Metropolitan Health Authority. The research grant paid for direct costs of the study; the funding source did not participate in the design, collection, analysis or interpretation of the data, in the writing of the report, its conclusions or the decision to submit the paper for consideration for publication. The corresponding author participated actively in the study, had full access to all the study data and had final responsibility for the decision to submit the article for publicationes
dc.identifier.citationColorectal disease 2021, 23: 805-813 https.//doi.org/10.1111/codi.15438es
dc.identifier.issn1463-1318
dc.identifier.orcidhttps://orcid.org/0000-0002-8341-7658es
dc.identifier.orcidhttps://orcid.org/0000-0001-8154-8550es
dc.identifier.orcidhttps://orcid.org/0000-0003-2860-2954es
dc.identifier.orcidhttps://orcid.org/0000-0001-5012-6945es
dc.identifier.orcidDOI: 10.1111/codi.15438
dc.identifier.urihttp://hdl.handle.net/20.500.12254/2140
dc.language.isoenes
dc.publisherWileyes
dc.relation.ispartofseriesColorectal Disease;Vol.23, issue 4
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subject.otherColon canceres
dc.subject.otherMinimal residual diseasees
dc.subject.otherNeutrophil to lymphocyte ratioes
dc.subject.otherProgression free survivales
dc.titleThe association of the neutrophil lymphocyte ratio with the presence of minimal residual disease and outcome in patients with stage ii colon cancer treated with surgery alonees
dc.typeArtículoes
dcterms.accessRightsEl artículo completo no puede ser publicado en el Repositorio Institucional debido a los permisos de copyright definidos por la editorial publicadora
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
638 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos de Revistas